WEMURAFENIB JAKO SELEKTYWNY INHIBITOR KINAZY SERONINOWO-TREONINOWEJ B-RAF STOSOWANY W LECZENIU CZERNIAKA

Krzysztof Kubica, Aleksander Mazurek

Bibliografia

1.    Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol 2009, 129(7), 1666–1674.

2.    Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009, 27(1), 3–9.

3.    Erdmann F, Lortet-Tieulent J, Schüz J, Zeeb H, Greinert R, Breitbart EW, Bray F. International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk? Int J Cancer 2013, 132(2), 385–400.

4.    Bucheit AD, Davies MA. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol 2014, 87(3) ,381–389.

5.    Cancer Facts and Figures 2016. American Cancer Society 2016.

6.    Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94(2), 153–156.

7.    Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: The role of physician examination and self-examination of the skin. CA Cancer J Clin 1985, 35(3), 130–151.

8.    Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. The Lancet 2005, 365(9460), 687–701.

9.    Ford D, Bliss JM, Swerdlow AJ, Armstrong BK, Franceschi S, Green A, Holly EA, Mack T, MacKie RM. Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995, 62(4), 377–381.

10.  Goldstein AM, Tucker MA. Genetic epidemiology of familial melanoma. Dermatol Clin 1995, 13(3), 605–612.

11.  Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001, 63(1–3), 8–18.

12.  Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003, 22(20), 3042–3052.

13.  Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastin BC. Improving Melanoma Classification by Integrating Genetic and Morphologic Features. PLOS Med 2008, 5(6), e120.

14.  Azoury SC, Lange JR. Epidemiology, risk factors, prevention, and early detection of melanoma. Surg Clin North Am 2014, 94(5), 945–962.

15.  Michael Binder, Scott Menzies. Computer aided instrumentation for the diagnosis of primary melanoma. CRC Press 2003, 234–240.

16.  Cook MG, Clarke TJ, Humphreys S, Fletcher A, McLaren KM, Smith NP, Stevens A, Theaker JM, Melia J. The evaluation of diagnostic and prognostic criteria and the terminology of thin cutaneous malignant melanoma by the CRC Melanoma Pathology Panel. Histopathology 1996, 28(6), 497–512.

17.  Krauss G. Biochemistry of Signal Transduction and Regulation. Wiley-VCH Verlag GmbH & Co. KGaA 2003.

18.  Ubersax JA, Ferrell Jr JE. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol 2007, 8(7), 530–541.

19.  Cohen P. Protein kinases--the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002, 1(4), 309–315.

20.  Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9(1), 28–39.

21.  Hidaka H, Kobayashi R. Pharmacology of Protein Kinase Inhibitors. Annu Rev Pharmacol Toxicol 1992, 32(1), 377–397.

22.  Li R, Stafford JA, editors. Protein Inhibitor Drugs 2009.

23.  Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012, 11(11), 873–886.

24.  Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM. Inhibitors of Protein Kinase Signaling Pathways Emerging Therapies for Cardiovascular Disease. Circulation 2004, 109(10), 1196–1205.

25.  Traxler P. Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opin Ther Targets 2003, 7(2), 215–234.

26.  Kose³a H, ¦witaj T, Rutkowski P. BRAF and MEK inhibitors in therapy of advanced melanoma. Oncol Clin Pract 2011, 7(5), 246–253.

27.  Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall C, Springer CJ, Barford D, Marais R. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF. Cell 2004, 116(6), 855–867.

28.  Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007, 26(22), 3100–3112.

29.  Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004, 6(4), 313–319.

30.  Swaika A, Crozier JA, Joseph RW. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther 2014, 8, 775–787.

31.  Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7(10), 3129–3140.

32.  Niezgoda A, Niezgoda P, Czajkowski R. Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. BioMed Res Int BioMed Res Int 2015.

33.  Richman J, Martin-Liberal J, Diem S, Larkin J. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Expert Opin Pharmacother 2015, 16(9), 1285–1297.

34.  da Rocha Dias S, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JHM, Giuliani R, Pignatti F. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2013, 49(7), 1654–1661.

35.  Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O`Day SJ, Sosman JA, Kirkwood JM, Eggermont A, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011, 364(26), 2507–2516.

36.  Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res MCR 2008, 6(5), 751–759.

37.  Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F. Metastatic melanoma - a review of current and future treatment options. Acta Derm Venereol 2015, 95(5), 516–524.

38.  McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbe C, Jouary T, Schadendorf D, O`Day SJ, Kirkwood JM, Eggermont A, Dreno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15(3), 323–332.

39.  Ravnan MC, Matalka MS. Vemurafenib in Patients With BRAF V600E Mutation–Positive Advanced Melanoma. Clin Ther 2012, 34(7), 1474–1486.

40.  Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJC, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464(7287), 431–435.

41.  Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010, 23(2), 190–200.

42.  Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468(7326), 973–977.

43.  Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487(7408), 500–504.

44.  Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffatt J, Sutherin DP, Koeppen H, Merchant M, Neve R, Settleman J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487(7408), 505–509.

45.  Hernandez-Davies JE, Tran TQ, Reid MA, Rosales KR, Lowman XH, Pan M, Moriceau G, Yang Y, Wu J, Lo RS, Kong M. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J Transl Med 2015, 13:210. 1-11

46.  Garber K. Melanoma Drug Vindicates Targeted Approach. Science 2009, 326(5960), 1619–1619.

47.  Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman PB. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2010, 28(1). suppl; abstr nr 9000.

48.  Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O`Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. N Engl J Med 2010, 363(9), 809–819.

49.  Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos S, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib. N Engl J Med 2012, 366(8), 707–714.

50.  Funck-Brentano E, Alvarez JC, Longvert C, Abe E, Beauchet A, Funck-Brentano C, Saiag P. Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. Ann Oncol Off J Eur Soc Med Oncol ESMO 2015, 26(7), 1470–1475.

51.  Kramkimel N, Sakji L, Schoemann A, Golmard J, Rosencher E, Theodore C, Goldwasser F. Severe skin rash during vemurafenib treatment: A predictive factor of early positive response in metastatic melanoma? J Clin Oncol 2014, 32(5). suppl; abstr nr 9092.

52.  Ribas A, Zhang W, Chang I, Shirai K, Ernstoff MS, Daud A, Cowey CL, Daniels G, Seja E, O`Laco E, Glaspy JA, Chmielowski B, Hill T, Joe AK, Grippo JF The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol 2014, 54(4), 368–374.

53.  Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, Thomas M, Vagner S, Favre M, Tomasic G, Wechsler J, Lacroix L, Robert C. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013, 24(6), 1691–1697.

54.  Boyd KP, Vincent B, Andea A, Conry RM, Hughey LC. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J Am Acad Dermatol 2012, 67(6), 1375–1379.

55.  Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, Kim CC, McCormack C, Myskowski PL, Spleiss O, Trunzer K, Su F, Nelson B, Nolop KB, Grippo JF, Lee RJ, Klimek MJ, Troy JL, Joe AK. Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma. The Oncologist 2013, 18(3), 314–322.

56.  Jhaveri KD, Sakhiya V, Fishbane S. Nephrotoxicity of the braf inhibitors vemurafenib and dabrafenib. JAMA Oncol 2015, 1(8), 1133–1134.

57.  Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N Engl J Med 2014, 371(20), 1867–1876.